By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree

OraGrowtH Trials is a clinical trial program involving the oral investigational drug, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an oral tablet and different from currently approved injections of recombinant human growth hormone (rhGH) for children with Growth Hormone Deficiency.

Watch the video to learn more about the OraGrowtH210 Trial.


Below are clinical trials involving LUM-201

A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve to Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD) 


This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201. 

Phase: 2 

Status: Active, not recruiting 

Detailed information about the OraGrowtH210 Trial
( Identifier: NCT04614337)
can be found at

Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of LUM-201 in Children with Growth Hormone Deficiency

The goals of this single site trial are to study the pharmacokinetics and pharmacodynamics of LUM-201 and the effects of LUM-201 administration on growth hormone release over time in children with pediatric growth hormone deficiency (PGHD).

Phase: 2

Status: Active, not recruiting

Detailed information about the OraGrowtH212 Trial
( Identifier: NCT04806854)
can be found at